Off-the-Shelf immune cells battle tough leukemia in new trial
Disease control
Recruiting now
This study is testing a new type of cell therapy called UCART22 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatments. The main goals are to find a safe and effective dose and see if the treatment can help control th…
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC